Breakthrough Treatment May Reduce Cervical Cancer Deaths by 35%: Study

New Treatment Involves Additional Course of Chemotherapy Using Affordable Drugs Prior to Standard Chemoradiation, Promising 'Biggest Improvement in Two Decades' for Cervical Cancer Patients Globally

• The breakthrough treatment for cervical cancer involves a six-week course of carboplatin and paclitaxel chemotherapy before standard chemoradiation. It's predicted to reduce the death rate by 35%.
• The research was conducted by scientists from the University College London Hospitals and presented at the European Society for Medical Oncology conference. Cancer Research UK funded the study and expects the treatment to be adopted by clinics.
• The trial involved 500 women from the United Kingdom, Mexico, India, Italy, and Brazil, with half receiving the breakthrough treatment and half receiving standard chemoradiation. The women were monitored across 10 years.
• After five years, 80% of the patients who received the new treatment were alive, and 73% had not experienced a return or spread of their cancer. In the control group, 73% of women were still alive, and 64% did not experience a return or spread of their cancer.
• The existing drugs used in the new treatment are not only affordable but already approved for use, meaning their incorporation into standard treatments could be relatively quick.

3 Articles

The Messenger People Sky News